Trial Profile
Phase II trial of Tarceva [erlotinib] following concurrent chemo-radiotherapy as first line therapy in patients with unresectable non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Mar 2014 Primary endpoint of progression-free rate has been met, according to results published in the Cancer Chemotherapy and Pharmacology.
- 01 Mar 2014 Status changed from recruiting to completed according to results published in the Cancer Chemotherapy and Pharmacology.